pemphigus vulgaris mouth - HEALTHY
Monthly Prescribing Reference: Rituximab Compared With Mycophenolate Mofetil in Pemphigus Vulgaris Trial Rituximab was found to be superior to mycophenolate mofetil (MMF) in adult patients with severe pemphigus vulgaris, according to new phase 3 trial data. Rituximab was found to be superior to ... Business Wire: Phase III PEMPHIX Study Showed That Genentech’s Rituxan (Rituximab) is Superior to Standard of Care in Achieving Sustained Remission in Patients with Pemphigus Vulgaris Phase III PEMPHIX Study Showed That Genentech’s Rituxan (Rituximab) is Superior to Standard of Care in Achieving Sustained Remission in Patients with Pemphigus Vulgaris Healio: Patients with pemphigus vulgaris more likely to achieve sustained complete remission with Rituxan Patients with pemphigus vulgaris more likely to achieve sustained complete remission with Rituxan European Medical Journal: New Risk Score Predicts Laryngeal Involvement in Pemphigus Vulgaris New clinical score predicts laryngeal involvement in pemphigus vulgaris, helping reduce unnecessary procedures while identifying high risk patients.
Context Explanation
The American Journal of Managed Care: Trial Finds Rituximab Is Superior to Mycophenolate Mofetil in Treating Pemphigus Vulgaris A phase 3 trial explored which treatment option for pemphigus vulgaris, a rare skin disease, resulted in better outcomes after 52 weeks. In patients with pemphigus vulgaris, rituximab was superior to ... Trial Finds Rituximab Is Superior to Mycophenolate Mofetil in Treating Pemphigus Vulgaris